The therapeutic efficacy of anti-PD-1 antibodies has been shown in certain cancer types5; however, clinical trials demonstrated that patients with sarcomas were refractory to PD-1 inhibitors showing only ∼5% partial response in patients with bone sarcomas.6 This evidence concerns the gene PDCD1 and cancer.